tiprankstipranks
Mangalam Organics Ltd (IN:MANORG)
:MANORG
India Market
Want to see IN:MANORG full AI Analyst Report?

Mangalam Organics Ltd (MANORG) AI Stock Analysis

0 Followers

Top Page

IN:MANORG

Mangalam Organics Ltd

(MANORG)

Select Model
Select Model
Select Model
Neutral 61 (OpenAI - 5.2)
Rating:61Neutral
Price Target:
₹504.00
▲(3.86% Upside)
Action:Reiterated
Date:06/01/26
Technical strength (price above major moving averages with positive MACD) supports the score, but overall fundamentals are constrained by negative operating/free cash flow and rising leverage despite the earnings recovery. Valuation is moderate and does not materially offset the cash-flow and balance-sheet risk.
Positive Factors
Revenue & Earnings Recovery
Consistent revenue growth and a return to positive net income represent durable demand for the company’s products and an operational turning point. Sustained top-line expansion with earnings recovery supports reinvestment, customer retention, and incremental margin improvement over the next 2–6 months.
Negative Factors
Rising Leverage
A sharp rise in debt materially increases financial risk and interest burden, reducing flexibility to invest or withstand demand shocks. Higher leverage constrains strategic options, heightens refinancing risk, and makes the company more vulnerable if operating performance slips over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Earnings Recovery
Consistent revenue growth and a return to positive net income represent durable demand for the company’s products and an operational turning point. Sustained top-line expansion with earnings recovery supports reinvestment, customer retention, and incremental margin improvement over the next 2–6 months.
Read all positive factors

Mangalam Organics Ltd (MANORG) vs. iShares MSCI India ETF (INDA)

Mangalam Organics Ltd Business Overview & Revenue Model

Company Description
Operating from India, Mangalam Organics Limited is a key producer, distributor, and international seller of terpene-based chemicals and synthetic resin compounds. Its business activities are distinctly categorized under Terpene Operations and Synt...
How the Company Makes Money
Mangalam Organics primarily makes money by manufacturing and selling specialty organic chemicals, with revenues largely driven by (1) camphor and camphor derivatives and (2) terpene chemicals/derivatives supplied to downstream consumer and industr...

Mangalam Organics Ltd Financial Statement Overview

Summary
Income statement is improving with steady revenue growth and a recovery back to positive earnings, but the balance sheet shows materially higher leverage and cash flow quality is weak with negative operating cash flow and deeply negative free cash flow in FY2025–FY2026.
Income Statement
62
Positive
Balance Sheet
48
Neutral
Cash Flow
25
Negative
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue5.78B6.23B5.30B4.94B4.93B4.91B
Gross Profit2.59B2.17B2.57B1.13B701.20M1.47B
EBITDA783.42M878.26M589.13M390.38M-24.27M924.25M
Net Income242.13M257.56M125.97M42.86M-272.25M537.43M
Balance Sheet
Total Assets7.29B7.40B6.24B4.85B5.06B5.60B
Cash, Cash Equivalents and Short-Term Investments411.72M205.09M189.27M20.19M12.79M12.78M
Total Debt3.52B3.59B2.72B1.73B1.90B2.12B
Total Liabilities4.21B4.21B3.30B2.05B2.30B2.56B
Stockholders Equity3.09B3.19B2.93B2.81B2.76B3.04B
Cash Flow
Free Cash Flow-769.42M-907.41M-751.15M327.48M361.57M-1.84B
Operating Cash Flow-281.34M-272.47M-78.44M727.23M769.23M-841.04M
Investing Cash Flow-381.05M-600.78M-670.47M-395.09M-407.80M-995.25M
Financing Cash Flow673.44M879.76M736.26M-325.52M-355.77M1.83B

Mangalam Organics Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price485.25
Price Trends
50DMA
506.81
Positive
100DMA
462.41
Positive
200DMA
488.50
Positive
Market Momentum
MACD
-9.47
Positive
RSI
50.67
Neutral
STOCH
83.50
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANORG, the sentiment is Positive. The current price of 485.25 is below the 20-day moving average (MA) of 518.53, below the 50-day MA of 506.81, and below the 200-day MA of 488.50, indicating a neutral trend. The MACD of -9.47 indicates Positive momentum. The RSI at 50.67 is Neutral, neither overbought nor oversold. The STOCH value of 83.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MANORG.

Mangalam Organics Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
₹7.13B30.2515.71%-3.48%
65
Neutral
₹6.48B12.901.23%-4.84%-8.30%
64
Neutral
₹29.55B19.810.09%15.19%9.27%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
₹4.61B19.2617.46%101.58%
54
Neutral
₹3.29B26.570.25%30.35%-15.12%
52
Neutral
₹7.64B141.041.07%-14.55%-74.70%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:MANORG
Mangalam Organics Ltd
538.55
-60.55
-10.11%
IN:AARTISURF
Aarti Surfactants Ltd.
388.55
-151.45
-28.05%
IN:CHEMCON
Chemcon Speciality Chemicals Ltd
194.70
11.51
6.28%
IN:FAIRCHEMOR
Fairchem Organics Ltd
606.50
-316.06
-34.26%
IN:JAYAGROGN
Jayant Agro-Organics Limited
215.95
-26.27
-10.85%
IN:ROSSARI
Rossari Biotech Ltd
533.40
-128.50
-19.41%

Mangalam Organics Ltd Corporate Events

Mangalam Organics Says Share Price Surge Is Market-Driven, No Undisclosed News
May 7, 2026
Mangalam Organics Ltd has responded to a query from the National Stock Exchange after a significant movement was observed in its share price. The company stated it is fully compliant with SEBI’s disclosure regulations and has been promptly r...
CRISIL Reaffirms Mangalam Organics’ Rs 397-Crore Bank Facility Ratings on Watch
Apr 14, 2026
Mangalam Organics Ltd has announced that CRISIL Ratings has reviewed and reaffirmed the company’s credit ratings on its bank facilities totaling Rs. 397 crore. The long-term rating remains at CRISIL BBB+ and the short-term rating at CRISIL A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 01, 2026